WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...

TANZANIA is among countries expected to benefit from the upcoming rollout of injectable lenacapavir for HIV prevention, following a landmark recommendation by the World Health Organization (WHO).

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government says it has saved the lives of over 25 million people around the world ...

At Essence Festival’s Global Black Economic Forum, Braxton joined Dr. Contessa and Raheem DeVaughn to speak candidly about HIV prevention, breast health, and taking control of your body.

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

Centre for Epidemiological Modelling and Analysis (CEMA), have released results of three studies that could significantly ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...

The third study, Twiga , is an ongoing five-year observational study tracking comorbidities in both HIV-positive and HIV-negative individuals aged 60 and above. It was initiated to better understand ...

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and ...